Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart condition's hidden toll: new study asks patients about life quality

NCT ID NCT07075445

Knowledge-focused Sponsor: Thryv Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand how Long QT Syndrome types 2 and 3 affect the quality of life and daily burden of adults. Researchers will ask up to 200 participants to fill out questionnaires about their physical, emotional, and social well-being. No treatment is given; the goal is to gather information to help improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from cardiology and genetic clinics at academic and private medical centers across the United States, as well as through outreach efforts targeting individuals and families affected by inherited arrhythmia conditions. This includes engagement through community-based initiatives. The study population includes individuals with a genetically confirmed diagnosis of Long QT Syndrome type 2 or 3.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The participant is willing and provides written informed consent to participate in this study. 2. Male or female participant of at least 18 years of age, English-speaking. 3. Confirmed genetic diagnosis of LQT2 or 3, demonstrated by one of the following: * Genetic testing report (pathogenic or likely pathogenic (P/LP) mutation) in KCHN2 or SCN5a genes) or, * A signed physician's letter confirming genetic diagnosis of LQTS 2 or 3. 4. Documented QTc ≥ 480 ms within the last year, demonstrated by one of the following: * 12-lead electrocardiogram (ECG), or * A signed physician's letter confirming an ECG demonstrating QTc value ≥ 480 ms. 5. The participant is able to operate a smartphone and a companion watch. \*The number of participants with QTc between 480 and 500 ms will be limited to 50. Exclusion Criteria: 1. Current participation in another clinical trial involving a drug or device. 2. Participants unwilling to use an iPhone or Apple Watch for the duration of the study. 3. Known diagnosis of Brugada Syndrome 4. Participants unwilling to comply with outlined procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long QT syndrome 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long QT syndrome 2 long QT syndrome 3 Long QT syndrome type 3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long QT syndrome 2 Long QT syndrome type 3

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • East Carolina University

    RECRUITING

    Greenville, North Carolina, 27858, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.